Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

Image Modified


Scope 

Project

Scope 

The goals of this project are is to obtain broad industry and CRO feedback on the current publicly available OCE/OOD standard safety data request (found at: https://www.fda.gov/media/133252/download) and assist with the development of resources to assist sponsors Sponsors with implementation of these data specifications.

There is tremendous variability and inconsistency in the use of the CDISC ADaM data standard in safety datasets for oncology NDA/BLA applications submitted to FDA. This variability leads to inefficiency in review for the FDA and multiple information requests to applicants during the course of the review to resolve inconsistencies in analyses between FDA and applicants. The Oncology Centre of Excellence (OCE)/Office of Oncologic Diseases (OOD) has developed a pilot standard safety data request for datasets submitted with NDA/BLA applications and instructions for conducting select safety analyses to create a common set of data elements with common use of these variables for safety analyses. The stakeholders Stakeholders include FDA reviewers and analysts, industry, CROs, and software developers.



Status
colourBlue
titleCurrent Status
Q3/4 2022

This project is currently on hold, the team will reach out for volunteers for the kick off of phase 2



Project LeadsEmail
Abhilasha Nairabhilasha.nair@fda.hhs.gov
Chris Pricechris.price@phuse.global Meredith Chukmeredith.chuk@fda.hhs.gov
Peter Schotland

peter.schotland@fda.hhs.gov

Wendy Dobson Katie Warren

(PHUSE Project

Manager

Assistant)wendy@phuse

katie@phuse.global








DeliverablesTimelines
Feedback on publicly available OCE/OOD safety data request.Q2 2021
Development of basic resources for sponsors to assist implementation (e.g. CRF design to collect relevant data and linkages for adverse events and dataset preparation for laboratory analyses or other resources requested or found to be needed during the feedback process)
Q2

Status
colourBlue
titleCurrent Status
Q12021

This is a new project which will commence in February. Project MembersCompanyBhupendra MistryRocheCathy BezekAstellasCindy MarabottiSanofiDiane WoldCDISCGopi VegesnaAstellasGreg Ball MerckGregory PurnsleyPfizerHitesh ThackerCovanceHong QiMerckJoy GeMerckKaren YingGSKKen MaahsJanssen Research and DevelopmentLihui Deng BMS Lindsay McLeanPharstarMarleen NijsJanssen Research and Development

Matt Smith 

Pfizer

Maxime Rouch 

SanofiPaul FrostGEM ProgrammingPavan KumarGSKPeter Bonata BayerBayerSrinivas KolamuriNovartisSuriaya WalshAstraZenecaSuwen LiRoche

Tatiana Sotingco

Janssen Research and DevelopmentTim YoungGSKVenkata Rajesh DatlaGenmabVishnu DabbiruGSKWenyun JiAbbVieWhitney BoeckelGSKWilliam PaloAbbVie
.Q2 2021